ProMIS reports positive blinded 6-month interim data for PMN310 in Alzheimer's Phase 1b trial

ProMIS Neurosciences Inc.

No ARIA-E observed across all genotypes; 4.4% total ARIA (all mild, asymptomatic ARIA-H) with no drug-related discontinuations.
61% of patients were APOE4 carriers (11% homozygotes); no ARIA-E in any genotype, including this high-risk group.
68.5% of patients had decline in plasma pTau217; 62.5% had decline in CSF MTBR-tau243, consistent with target engagement.
Trial remains blinded; unblinded 12-month topline efficacy data expected in Q1 2027.
PMN310 designed to selectively bind toxic amyloid-beta oligomers while avoiding plaque, aiming to decouple efficacy from ARIA risk.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.